Default company panoramic image

Seryx Biomedical, Inc.

Seryx Biomedical has developed a novel, protein-based ophthalmic solution for the treatment of dry eye disease.

  • Stage Prototype Ready
  • Industry Biotechnology
  • Location Maple Grove, MN, USA
  • Currency USD
  • Founded September 2010
  • Employees 5
  • Website

Company Summary

Seryx Biomedical is a start up company developing a novel eye drop for the treatment of dry eye disease which affects over 75M people worldwide. Silk fibroin is the main component of the ViSERA™ eye drop, capitalizing on its properties of an anti-inflammatory, pro-healing, protein network which will stabilize the natural tear film and improve ocular comfort. Over 40,000 eye care specialists will prescribe our products to their patients.


  • Default avatar
    Jon St. Germain
    Chief Executive Officer

    Mr. St. Germain is an accomplished executive with over 20 years of experience in the medical industry having developed many products from concept through commercialization. Prior to joining Seryx, Mr. St. Germain held senior positions at Torax Medical developing an implantable device for the treatment of acid reflux disease and St. Jude Medical where he was the Vice President of R&D/Program Management. He is an inventor on over 40 patents.

  • Default avatar
    Brian Lawrence
    Chief Technical Officer

    Dr. Lawrence is a company co-founder with a PhD in biomedical engineering from Cornell University. He has been actively researching devices fabricated from silk for ocular applications and silk fibroin processing for the last 8 years at Tufts University and Cornell University. Brian is considered an expert in the silk processing field and has numerous publications and written a textbook chapter on the subject.

  • Default avatar
    Mark Rosenblatt

    Dr. Rosenblatt is a co-founder, Board member, Associate Professor of Ophthalmology and the Director of the Margaret M. Dyson Vision Research Institute at Weill Cornell Medical College. He is the author of numerous scientific and clinical articles in leading journals, and lectures nationally and internationally on topics related to corneal disease.

  • Default avatar
    Denise Barbut
    Board Chairperson

    Dr. Barbut is a former professor of Neurology at Cornell University and is a company co-founder and chairman of the Board. She is a serial entrepreneur having founded nine medical companies with inventorship on nearly 300 patents.

  • Default avatar
    David Enfanger
    Development Director

    Dr. Enfanger has a Phd from Iowa State University in molecular biogioy.

  • Default avatar
    Brian Levy
    Board Director


  • Default avatar
    Tom Letcher, Oppenheimer, Wolff & Donnelly
    Default avatar
    Nancy Ness, CFO